Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
Want to see PTGX full AI Analyst Report?
PTGX Stock Chart & Stats
$105.98
-$0.87(-2.26%)
At close: 4:00 PM EST
$105.98
-$0.87(-2.26%)
Day’s Range― - ―
52-Week Range$41.29 - $107.84
Previous CloseN/A
Volume120.35K
Average Volume (3M)869.10K
Market Cap
$6.29B
Enterprise Value$6.34B
Total Cash (Recent Filing)$567.36M
Total Debt (Recent Filing)$10.32M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
May 06, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding63,808,716
10 Day Avg. Volume653,616
30 Day Avg. Volume869,095
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.03
Price to Sales (P/S)120.66
P/FCF Ratio99.01
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue137.78
Enterprise Value/Gross Profit138.91
Enterprise Value/Ebitda-44.30
Forecast
1Y Price Target
$112.00Price Target Upside5.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)3.23
Revenue Forecast (FY)$441.55M
Bulls Say, Bears Say
Bulls Say
Clinical Readthrough And Indication ExpansionStrong phase results and planned head-to-head and psoriatic arthritis studies could support label expansion beyond psoriasis and create additional commercial upside if outcomes are favorable.
Platform Validation And Pipeline UpsideApproval validates the company’s oral peptide platform, increasing confidence in multiple development candidates and enhancing strategic value for potential partnerships or licensing deals.
Regulatory Approval And Label ExpansionRegulatory approval of Icotyde with inclusion of adolescent patients and a smaller-than-expected food effect expands the addressable population and lowers regulatory uncertainty, supporting broader clinical adoption.
Bears Say
Partner-led Commercialization And Revenue VisibilityReliance on Johnson & Johnson to lead commercialization leaves limited visibility on launch execution and timing of royalties, increasing near-term revenue uncertainty for the company.
Payer Access And Market Penetration RiskUncertainty about payer coverage and whether new prescriptions represent true market growth versus switching from established biologics could constrain uptake and pressure revenue assumptions.
Research Conflicts And Perceived ObjectivityDisclosed potential conflicts of interest at a research firm could undermine the credibility of favorable reports and contribute to increased investor skepticism and stock volatility.
Protagonist Therapeutics News
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $41.28 and its highest was $107.84 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $6.29B.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is May 06, 2026 which is in 7 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Feb 25, 2026. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.567 by -$0.123.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -0.49.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 63,808,716 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.567. Following the earnings report the stock price went up 1.481%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Currently, no hedge funds are holding shares in PTGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protagonist Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$112.00 (5.68% Upside)
$112.00 (5.68% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 353.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
128.99%
12-Months-Change
Fundamentals
Return on Equity
-19.89%
Trailing 12-Months
Asset Growth
-10.30%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PTGX Stock 12 Month Forecast
Average Price Target
$112.00
▲(5.68% Upside)
Technical Analysis
ADMA Biologics
―
Zai Lab
―
―
Mirum Pharmaceuticals
―
Ascentage Pharma Group International Unsponsored ADR
―
Ownership Overview
1.22% Insiders
21.92% Mutual Funds
0.60% Other Institutional Investors
50.51% Public Companies and
Individual Investors